Literature DB >> 7535286

Mapping a putative tumor suppressor gene on chromosome 9 bands p21-p22 with microdissection probes.

S K Bohlander1, M H Dreyling, F Hagos, L Sveen, O I Olopade, M O Díaz.   

Abstract

Deletions of the short arm of chromosome 9 have been observed in a number of malignant cell lines and primary tumor samples using cytogenetic and molecular techniques. These tumors include acute lymphoblastic leukemias, lymphomas, gliomas, melanomas, mesotheliomas, bladder cancer, and lung cancer. The smallest region of overlap (SRO) of these deletions is thought to contain a tumor suppressor gene. A microdissection library was constructed from bands 9p21-p23 to obtain DNA probes that would be useful in further defining the limits of the deletions. Eight single-copy probes were found to be homozygously deleted in at least 1 of the 10 cell lines examined. The mapping of these 8 clones using a panel of cell lines with deletions revealed that 3 probes mapped telomeric to the SRO and 5 clones mapped centromeric to the SRO.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7535286     DOI: 10.1006/geno.1994.1608

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  2 in total

1.  Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21.

Authors:  O I Olopade; H M Pomykala; F Hagos; L W Sveen; R Espinosa; M H Dreyling; S Gursky; W M Stadler; M M Le Beau; S K Bohlander
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

2.  Ladder-like amplification of the type I interferon gene cluster in the human osteosarcoma cell line MG63.

Authors:  Narasimharao V Marella; Michael J Zeitz; Kishore S Malyavantham; Artem Pliss; Sei-ichi Matsui; Sandra Goetze; Juergen Bode; Ivan Raska; Ronald Berezney
Journal:  Chromosome Res       Date:  2008-11-15       Impact factor: 5.239

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.